The diagnosis and management of adults with spasticity

Handbook of Clinical Neurology

Volumn 110, Issue , 2013, Pages 145-160

  Balakrishnan, Sudha ^a   Ward, Anthony B ^b  

^a West Midlands Rehabilitation Centre   (United Kingdom)

^b STAFFORDSHIRE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872313999     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52901-5.00013-7     Document Type: Chapter

References (92)

1. Ada L., O'Dwyer N. Do associated reactions in the upper limb after stroke contribute to contracture formation?. Clin Rehabil 2001, 15:186-194.
2. Albright A.L., Gilmartin R., Swift D., et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003, 98:291-295.
3. Ashworth B. Preliminary trial of carisprodal in multiple sclerosis. Practitioner 1964, 192:540-542.
4. Axelson H.W., Hagbarth K.E. Human motor control consequences of thixotropic changes in muscular short-range stiffness. J Physiol 2001, 535:279-288.
5. Bakheit A.M. Muscle spasticity and its management. Botulinum Toxin: Treatment of Muscle Spasticity 2001, Blackhall Publishing, London.
6. Bakheit A.M.O., Thilmann A.F., Ward A.B., et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000, 31:2402-2406.
7. Bennett D.J., Li Y., Harvey P.J., et al. Evidence for plateau potentials in the tail motor neurons of awake chronic spinal rats with spasticity. J Neurophysiol 2001, 86:1979-1982.
8. Ben Smail D., Peskine A., Roche N., et al. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 2006, 12:101-103.
9. Bes A., Eyssette M., Pierrot-Deseilligny E., et al. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988, 10:709-718.
10. Bodine-Fowler S.C., Allsing S., Botte M.J. Time course of muscle atrophy and recovery following a phenol-induced nerve block. Muscle Nerve 1996, 19:497-504.
11. Bogle Thorbahn L.D., Newton R.A. Use of the Berg Balance Test to predict falls in elderly persons [see comment]. Phys Ther 2006, 76:576-583.
12. Bohannon R.W., Smith M.B. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987, 67:206-227.
13. Burke D. Spasticity as an adaptation to pyramidal tract injury. Adv Neurol 1988, 47:401-422.
14. Burkel W.E., McPhee M. Effect of phenol injection on peripheral nerve of rat: electron microscope studies. Arch Phys Med Rehabil 1970, 51:391-397.
15. Cendrowski W., Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur J Neurol 1977, 16:257-262.
16. Chyatte S.B., Birdsong J.H., Bergman B.A. The effects of dantrolene sodium on spasticity and motor performance in hemiplegia. South Med J 1971, 64:180-185.
17. Denny-Brown D. The Cerebral Control of Movement 1966, Liverpool University Press, Liverpool.
18. Dewald J.P.A., Given J.D. Electrical stimulation and spasticity reduction. Fact or fiction?. Physical Medicine and Rehabilitation: State of the Art Reviews 1994, 8:507-522.
19. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003, 43:S16-S24.
20. Dolly J.O., Aoki K. The structure and mode of action of botulinum toxins. Eur J Neurol 2006, 13:1-9.
21. Farmer S.E., Harrison L.M., Ingram D.A., et al. Plasticity of central motor pathways in children with hemiplegic cerebral palsy. Neurology 1991, 41:1504-1510.
22. Francisco G.E., Kothari S., Huls C. GABA agonists and gabapentin for spastic hypertonia. Phys Med Rehabil Clin N Am 2001, 12:875-888.
23. Francisco G.E., Latorre J.M., Ivanhoe C.B. Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury. Brain Inj 2007, 21:335-338.
24. Gelenberg A.J., Poskanzer D.C. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973, 23:1313-1315.
25. Giovannelli M., Borriello G., Castri P., et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007, 21:331-337.
26. Gracies J.M. Evaluation de la spasticité. Apport de l'echelle de Tardieu. Motricité Cérébrale 2001, 22:1-16.
27. Gracies J.M., Wilson L., Gandevia S.C., et al. Stretched position of spastic muscle aggravates their co-contraction in hemiplegic patients. Ann Neurol 1997, 42:438. -438.
28. Gracies J.M., Elovic E., McGuire J.R., et al. Traditional pharmacological treatments for spasticity. Part I: local treatments. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin 2002, 44-64. We Move, New York.
29. Guillaume D., Van Havenbergh A., Vloeberghs M., et al. A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil 2005, 86:2165-2171.
30. Hassan N., McLellan D.L. Double-blind comparison of single doses of DS103-282, baclofen, and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 1980, 43:1132-1136.
31. Hudgson P., Weightman D. Baclofen in the treatment of spasticity. Br Med J 1971, 4:155-157.
32. Hufschmidt A., Mauritz K. Chronic transformation of muscle in spasticity: a peripheral contribution to increased tone. J Neurol Neurosurg Psychiatry 1985, 48:676-685.
33. Hwang A.S., Wilcox G.L. Baclofen, gamma-aminobutyric acid B receptors and substance P in the mouse spinal cord. J Pharmacol Exp Ther 1989, 248:1026-1033.
34. Ivanhoe C.B., Reistetter T.A. Spasticity: the misunderstood part of the upper motor neurone syndrome. Am J Phys Med Rehabil 2004, 83:S3-S9.
35. Jebsen R.H., Taylor N., Trieschmann R.B., et al. An objective and standardized test of hand function. Arch Phys Med Rehabil 1969, 50:311-319.
36. Katz R.T., Rovai G.P., Brait C., et al. Objective quantification of spastic hypertonia: correlation with clinical findings. Arch Phys Med Rehabil Med 1994, 73:339-347.
37. Kelly R.E., Gautier-Smith P.C. Intrathecal phenol in the treatment of reflex spasms and spasticity. Lancet ii: 1959, 1102-1105.
38. Ketel W.B., Kolb M.E. Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin 1984, 9:161-168.
39. Ketelaer C.J., Ketelaer P. The use of Lioresal in the treatment of muscular hypertonia due to multiple sclerosis: spasticity: a topical survey. An International Symposium, Vienna, 1971 1972, 128-131. Huber, Vienna. W. Birkmayer (Ed.).
40. Killestein J., Uitdehaag B.M., Polman C.H. Cannabinoids in multiple sclerosis: do they have a therapeutic role?. Drugs 2004, 64:1-11.
41. Kirazli Y., On A.Y., Kismali B., et al. Comparison of phenol block and botulinum toxin type A in the treatment of spastic foot after stroke: a randomized double-blind trial. Am J Phys Rehabil Med 1998, 77:510-515.
42. Kirusek T., Sherman R. Goal attainment scaling: a general method of evaluating comprehensive mental health programmes. Community Ment Health J 1968, 4:443-453.
43. Knutsson E., Martensson A. Dynamic motor capacity in spastic paresis and its relation to prime mover dysfunction, spastic reflexes and agonist co-activation. Scand J Rehabil Med 1980, 12:93-106.
44. Krenz N.R., Weaver L.C. Sprouting of primary afferent fibres after spinal cord transection in the rat. Neuroscience 1998, 85:443-458.
45. Lance J.W. Symposium synopsis. Spasticity: Disordered Control 1980, 485-494. Yearbook Medical, Chicago. R.G. Feldman, R.R. Young, W.P. Koella (Eds.).
46. Lee K., Carson L., Kinnin E., et al. The Ashworth scale: a reliable and reproducible method of measuring spasticity. J Neurol Rehabil 1989, 3:205-208.
47. Mayer N.H. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin 2002, 1-10. We Move, New York.
48. Moore A., Naumann M. General and clinical aspects of treatment with botulinum toxin. Handbook of Botulinum Toxin Treatment 2003, 28-75. Blackwell Science, Oxford. 2nd edn. A. Moore, N. Naumann (Eds.).
49. Nance P.W., Bugaresti J., Shellengerger K., et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994, 44:S44-S52.
50. Nathan P. Some comments on spasticity and rigidity. New Developments in Electromyography and Clinical Neurophysiology 1973, 13-14. Karger, Basel. J.E. Desmedt (Ed.).
51. Newman P.M., Nogues M., Newman P.K., et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982, 23:31-35.
52. Pandyan A.D., Johnson G.R., Price C.I.M., et al. A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clin Rehabil 1999, 13:373-383.
53. Pandyan A.D., Gregoric M., Barnes M.P., et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005, 27:2-6.
54. Pellizzari R., Rossetto O., Schiavo G., et al. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999, 354:259-268.
55. Pinder R.M., Brogden R.N., Speight T.M., et al. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977, 13:3-23.
56. Platz T., Eickhof C., Nuyens G., et al. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil 2005, 27:7-18.
57. Pollmann W., Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008, 22:291-324.
58. Price G.W., Wilkin G.P., Turnbull M.J., et al. Are baclofen-sensitive GABA-B receptors present on primary afferent terminals of the spinal cord?. Nature 1984, 307:71-73.
59. Roden-Jullig A., Britton M., Gustafsson C., et al. Validation of four scales for the acute stage of stroke. J Int Med 1994, 236:125-136.
60. Rothwell J. Control of Human Voluntary Movement 1994, Chapman & Hall, London. 2nd edn.
61. Sahrmann S.A., Norton B.J. The relationship of voluntary movement to spasticity in the upper motor neurone syndrome. Trans Am Neurol Assoc 1977, 102:108-111.
62. Sheean G. Neurophysiology of spasticity. Upper Motor Neurone Syndrome and Spasticity: Clinical Management and Neurophysiology 2001, 12-78. Cambridge University Press, Cambridge. M.P. Barnes, G.R. Johnson (Eds.).
63. Sheean G. The pathophysiology of spasticity. Eur J Neurol 2002, 9:3-9.
64. Sherrington C.S. The Integrative Action of the Nervous System 1906, Yale University Press, New Haven.
65. Singer B.J., Dunne J.W., Singer K.P., et al. Velocity dependant passive plantar flexor resistive torque in patients with acquired brain injury. Clin Biomech 2003, 18:157-165.
66. Smith C., Birnbaum G., Carter J.L., et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology 1994, 44:S34-S43.
67. Smolenski C., Muff S., Smolenski-Kautz S. A double-blind comparative trial of a new muscle relaxant, tizanidine and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981, 7:374-383.
68. Sommerfeld D.K., Eek E.U., Svensson A.K., et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004, 35:134-139.
69. SPASM (A European Thematic Network to Develop Standardised Measures of Spasticity) CREST - Centre for Rehabilitation and Engineering Studies, University of Newcastle, Stephenson Building, Claremont Road, Newcastle upon Tyne, NE1 7RU, UK. Disabil Rehabil 2006, 28(Suppl 1):S1-S75.
70. Stein R., Nordal H.J., Oftedal S.I., et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen. Acta Neurol Scand 1987, 75:190-194.
71. Tardieu G., Shentoub S., Delarue R. A la recherche d'une technique de mesure de la spasticité. Rev Neurol (Paris) 1954, 91:143-144.
72. Tardieu C., Lespargot A., Tabary C., et al. For how long must the soleus muscle be stretched each day to prevent contracture?. Dev Med Child Neurol 1988, 30:3-10.
73. The United Kingdom Tizanidine Trial Group A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994, 44:S70-S78.
74. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 2009, 23:362-370.
75. Turner-Stokes L., Ashford S., Bhakta B., et al. Spasticity in adults: management using botulinum toxin: national guidelines 2009, Royal College of Physicians, London.
76. Utili R., Boitnott J.K., Zimmerman H.J. Dantrolene-associated hepatic injury: incidence and character. Gastroenterology 1977, 72:610-616.
77. Valle M.S., Casabona A., Sgarlata R., et al. The pendulum test as a tool to evaluate passive knee stiffness and viscosity of patients with rheumatoid arthritis. BMC Musculoskelet Disord 2006, 7:89.
78. Verplancke D., Snape S., Salisbury C.F., et al. A randomised controlled trial of the management of early lower limb spasticity following acute acquired severe brain injury. Clin Rehabil 2005, 19:117-125.
79. Wade D.T. Measurement in Neurological Rehabilitation 1992, Oxford University Press, Oxford.
80. Wagstaff A.J., Bryson H.M. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997, 53:435-452.
81. Wallace J.D. Summary of combined clinical analysis of controlled clinical trial with tizanidine. Neurology 1994, 44:S60-S68.
82. Ward A.B. Botulinum toxin in spasticity management. Br J Ther Rehabil 1999, 6:26-34.
83. Ward A.B. Use of botulinum toxin type A in spastic diplegia resulting from cerebral palsy. Eur J Neurol 1999, 6:S46-S48.
84. Ward A.B. A summary of spasticity management: a treatment algorithm. Eur J Neurol 2002, 9:48-52.
85. Ward A.B., Bhakta B., Barnes M.P., et al. Working Party Report on the Management of Adult Spasticity Using Botulinum Toxin Type A: a Guide to Clinical Practice 2001, Radius Healthcare, Byfleet.
86. Wartenburg R. Pendulousness of the legs as a diagnostic test. Neurology 1951, 1:18-24.
87. Weiser R., Terenty T., Hudgson P., et al. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner 1978, 221:123-127.
88. Wilkinson S.P., Portmann B., Williams R. Hepatitis from dantrolene sodium. Gut 1979, 20:33-36.
89. Wissel J., Ward A.B., Erztgaard P., et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009, 41:13-25.
90. World Health Organization International Classification of Functioning, Disability and Health: ICF 2001, WHO, Geneva.
91. Young R.R. Spasticity: a review. Neurology 1994, 44:512-520.
92. Zajicek J., Fox P., Sanders H., et al. UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study). Lancet 2003, 362:1517-1526.